{"id":"tamsulosin-bid","safety":{"commonSideEffects":[{"rate":"8-18","effect":"Retrograde ejaculation"},{"rate":"15-17","effect":"Dizziness"},{"rate":"7-21","effect":"Headache"},{"rate":"8-15","effect":"Asthenia/fatigue"},{"rate":"1-4","effect":"Orthostatic hypotension"},{"rate":"4-13","effect":"Rhinitis"}]},"_chembl":{"chemblId":"CHEMBL1200914","moleculeType":"Small molecule","molecularWeight":"444.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamsulosin selectively blocks alpha-1A adrenergic receptors located on smooth muscle cells in the prostate gland and bladder neck. By antagonizing these receptors, it reduces smooth muscle tone and tension in these tissues, thereby decreasing urinary obstruction and improving urinary symptoms associated with benign prostatic hyperplasia. The BID (twice daily) formulation indicates dosing twice per day, though extended-release once-daily formulations are more common.","oneSentence":"Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:03.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"}]},"trialDetails":[{"nctId":"NCT02483793","phase":"NA","title":"Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population","status":"WITHDRAWN","sponsor":"Phoenix Children's Hospital","startDate":"2015-07","conditions":"Disorder of Urinary Stent","enrollment":""},{"nctId":"NCT07134907","phase":"PHASE4","title":"The Efficacy and Safety of Qianweitai (Silodosin Capsule) Versus Tamsulosin in the Treatment of BPH","status":"COMPLETED","sponsor":"Shanghai Huilun Pharmaceutical Co., Ltd.","startDate":"2022-07-18","conditions":"BPH (Benign Prostatic Hyperplasia)","enrollment":110},{"nctId":"NCT06257576","phase":"PHASE3","title":"Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter","status":"RECRUITING","sponsor":"Emory University","startDate":"2024-02-26","conditions":"Postoperative Urinary Tract Infection","enrollment":212},{"nctId":"NCT06491108","phase":"PHASE3","title":"Medications for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-06-01","conditions":"Enlarged Prostate With Lower Urinary Tract Symptoms","enrollment":150},{"nctId":"NCT06266962","phase":"PHASE4","title":"Comparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome","status":"COMPLETED","sponsor":"University Hospital Olomouc","startDate":"2020-07-01","conditions":"Intraoperative Floppy Iris Syndrome, Cataract, Age-related Cataract","enrollment":164},{"nctId":"NCT03709992","phase":"NA","title":"Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:","status":"SUSPENDED","sponsor":"Mansoura University","startDate":"2020-12-18","conditions":"Ureter Stone, Quality of Life, Ureter Obstruction","enrollment":200},{"nctId":"NCT05551221","phase":"PHASE4","title":"The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia","status":"RECRUITING","sponsor":"Xintian Pharmaceutical","startDate":"2022-07-18","conditions":"Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms","enrollment":312},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":"Orthostatic Hypotension, Falls","enrollment":356},{"nctId":"NCT04552431","phase":"PHASE2","title":"Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-09-30","conditions":"Chronic Prostatitis With Chronic Pelvic Pain Syndrome","enrollment":196},{"nctId":"NCT04418635","phase":"NA","title":"Herbal Supplement Prosta-OK® Neo as an Adjunct Therapy in Patients With Mild to Severe Non-neurogenic Male Lower Urinary Tract Symptoms Receiving Tamsulosin Therapy","status":"UNKNOWN","sponsor":"Acrobio Healthcare Inc.","startDate":"2020-06-04","conditions":"Lower Urinary Tract Symptoms","enrollment":100},{"nctId":"NCT03799120","phase":"PHASE4","title":"Daily Versus Twice Per Day Tamsulosin for Ureteral Stent Symptoms","status":"UNKNOWN","sponsor":"Gundersen Lutheran Medical Foundation","startDate":"2019-02-18","conditions":"Ureteral Diseases","enrollment":80},{"nctId":"NCT02121613","phase":"PHASE4","title":"PERmixon® in LUTS Evaluation Study (PERLES)","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2014-04","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":833},{"nctId":"NCT01604811","phase":"PHASE4","title":"Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia)","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2012-06","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":206},{"nctId":"NCT00264017","phase":"","title":"Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis","status":"COMPLETED","sponsor":"Dattoli Cancer Center and Brachytherapy Research Institute","startDate":"2005-11","conditions":"Prostate Cancer Patients Undergoing External Radiation and Seed Implantation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tamsulosin BID","genericName":"Tamsulosin BID","companyName":"Gundersen Lutheran Medical Foundation","companyId":"gundersen-lutheran-medical-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}